Open Label Single-Arm Clinical Trial with Earvaru Beeja Kalka in the Management of Benign Prostatic Hyperplasia

被引:0
|
作者
Tripathy, Rabinarayan [1 ]
Athulya, A. [1 ]
Otta, Susmita P. [2 ]
机构
[1] Amrita Univ, Sch Ayurveda, Dept Shalya Tantra, Amritapuri Campus, Amritapuri, India
[2] CCRAS, Cent Ayurveda Res Inst Hepatobiliary Disorder, Bhubaneswar, India
关键词
vatashtila; Ervaru beeja kalka; Benign prostatic hypertrophy; mutraghata;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Benign prostatic hypertrophy (BPH) is a common condition in the aging men along with lower urinary tract symptoms (LUTS). The prevalence of BPH is proportional to age. It affects 70% of men above 70 years. It is the increase in the number of stromal and glandular epithelial cells in the periurethral transitional zone of the prostate. It can be correlated to vatashtila one among the mutraghata. BPH can be managed by a conservative and surgical treatment which includes anti-androgen therapy, alpha-blockers, aromatase inhibitors, prostatectomy, laser therapy, microwave treatment. As the patients are fairly old these complications are liable to occur in early postoperative days. Even conservative therapy has disadvantages like administering anti-androgen therapy causes impotence, aromatase inhibitors which are widely used have to lead to certain side effects like lassitude, depression, gynecomastia. According to surveys, the socioeconomic burden of BPH is tremendous, costing over $3 billion every year. In this situation, Ayurveda may be able to provide a treatment that is herbal and free from any adverse effects. This research work was carried out with the ultimate aim of finding the best cost-effective treatment of BPH in comparison with available Allopathic treatment. An extensive literature review reveals that Ervaru beeja kalka along with saindhava lavana and dhanyamla is an excellent remedy for mutraghata. Ervaru beeja kalka is an excellent mutrala, balya and dosha prashamana. Also, studies reveal that chemical constituents in cucumber seed can act on the signaling pathway of the proliferation of cancer cells i n the prostate. Because of all these reasons, the present study of Earvaru beeja kalka on BPH was done.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 50 条
  • [21] Pregabalin in the treatment of postmastectomy chronic pain: Results of an open label, single-arm clinical study
    Kaur, Navneet
    Kumar, Ashwani
    Saxena, Ashok Kumar
    Grover, Rajesh Kumar
    BREAST JOURNAL, 2019, 25 (03): : 465 - 468
  • [22] Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
    Bao, Q.
    Zhang, Z.
    Wen, J.
    Wan, R.
    Yang, X.
    Chen, X.
    Shen, Y.
    Zhang, W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1712 - S1712
  • [23] VAL-1221 for the treatment of patients with Lafora disease: study protocol for a single-arm, open-label clinical trial
    Muccioli, Lorenzo
    Vignatelli, Luca
    Tappata, Maria
    Mazzone, Serena
    Zenesini, Corrado
    Armstrong, Dustin
    Michelucci, Roberto
    Bisulli, Francesca
    BMJ OPEN, 2024, 14 (10):
  • [24] Dichloroacetate as a possible treatment for endometriosis-associated pain: a single-arm open-label exploratory clinical trial (EPiC)
    H. W. Leow
    M. Koscielniak
    L. Williams
    P. T. K. Saunders
    J. Daniels
    A. M. Doust
    M-C Jones
    G. D. Ferguson
    Y. Bagger
    A. W. Horne
    L. H. R. Whitaker
    Pilot and Feasibility Studies, 7
  • [25] Dichloroacetate as a possible treatment for endometriosis-associated pain: a single-arm open-label exploratory clinical trial (EPiC)
    Leow, H. W.
    Koscielniak, M.
    Williams, L.
    Saunders, P. T. K.
    Daniels, J.
    Doust, A. M.
    Jones, M-C
    Ferguson, G. D.
    Bagger, Y.
    Horne, A. W.
    Whitaker, L. H. R.
    PILOT AND FEASIBILITY STUDIES, 2021, 7 (01)
  • [26] Patient Satisfaction After Switching to Jatenzo (Oral Testosterone Undecanoate): Update on an Open-label, Single-arm Clinical Trial
    Reddy, Rohit
    Rivero, Marco-Jose
    Patel, Mehul
    Muthigi, Akhil
    Diaz, Parris
    Ramasamy, Ranjith
    EUROPEAN UROLOGY FOCUS, 2023, 9 (01): : 17 - 19
  • [27] Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial
    Wu, Chanyuan
    Wang, Qian
    Xu, Dong
    Li, Mengtao
    Zeng, Xiaofeng
    RHEUMATOLOGY, 2021, 60 (06) : 2629 - 2634
  • [28] Efficacy and safety of Abelmoschus manihot in treating chronic kidney diseases: A multicentre, open-label and single-arm clinical trial
    Sun, Xuefeng
    Li, Ping
    Lin, Hongli
    Ni, Zhaohui
    Zhan, Yongli
    Cai, Guangyan
    Liu, Chao
    Chen, Qinkai
    Wang, Wenge
    Wang, Xiaoqin
    Zhang, Peiqing
    Li, Peng
    Liang, Meng
    Zheng, Hongguang
    Wang, Niansong
    Miao, Lining
    Jin, Ruixia
    Guo, Zhiyong
    Wang, Yong
    Chen, Xiangmei
    PHYTOMEDICINE, 2022, 99
  • [29] Efficacy and Tolerability of a Combined Moxifloxacin/Dexamethasone Formulation for Topical Prophylaxis in Phacoemulsification: An Open-Label Single-Arm Clinical Trial
    Espiritu, Cesar Ramon G.
    Sy, Mary Ellen A.
    Tayengco, Tommee Lynne G.
    JOURNAL OF OPHTHALMOLOGY, 2011, 2011
  • [30] Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial
    Takazono, Takahiro
    Hosogaya, Naoki
    Fukushima, Koki
    Morio, Ryosuke
    Irifune, Satoshi
    Miyamura, Takuto
    Harada, Yosuke
    Nagayoshi, Yosuke
    Kondo, Akira
    Mihara, Tomo
    Fukuda, Yuichi
    Sasaki, Eisuke
    Sawai, Toyomitsu
    Imamura, Yoshifumi
    Morikawa, Toru
    Futsuki, Yoji
    Inoue, Yuichi
    Fukushima, Kiyoyasu
    Suyama, Naofumi
    Tanaka, Hikaru
    Hanaka, Tetsuya
    Shimabukuro, Ikuko
    Hata, Ryosuke
    Ota, Kenji
    Morimoto, Shimpei
    Nakada, Nana
    Ito, Yuya
    Yoshida, Masataka
    Takeda, Kazuaki
    Ide, Shotaro
    Iwanaga, Naoki
    Nemoto, Kazuki
    Funada, Midori
    Izumikawa, Koichi
    Yatera, Kazuhiro
    Yanagihara, Katsunori
    Mukae, Hiroshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (07) : 597 - 602